Latest news with #Summit
ILoveQatar.net
9 hours ago
- Business
- ILoveQatar.net
Google Cloud Summit Doha Marks Two Years, Showcases AI and Qatar's Digital Growth
Google Cloud hosted its second annual Google Cloud Summit in Doha, held under the patronage of His Excellency Mohammed bin Ali bin Mohammed Al Mannai, Minister of Communications and Information Technology, bringing together over 1,500 industry leaders, developers, and IT professionals. The Summit marks two years of the Google Cloud Doha region empowering local innovation and is set to explore the latest advancements in AI, data analytics, and cloud technologies. The event featured significant discussions and announcements on strategic collaborations, including key developments with the Ministry of Communications and Information Technology (MCIT) aimed at advancing Qatar's digital transformation journey. The Google Cloud Summit Doha showcased the vibrant tech ecosystem in Qatar and Google Cloud's commitment to it. Attendees experienced keynotes from Google Cloud executives and Qatari leaders, gained insights into transformative AI technologies like Gemini, AI Agents, and NotebookLM, heard compelling customer success stories, and participated in deep-dive sessions on data management and cybersecurity. This ongoing partnership with Qatar is poised to play a vital role in building a resilient, secure, and digitally advanced ecosystem in the nation. Mr. Sami Al Shammari, Assistant Undersecretary for Infrastructure and Operations Affairs at MCIT, stated: "Our collaboration with Google Cloud has served as a key enabler in Qatar's journey toward a knowledge-based, innovation-driven economy. Since the launch of the Doha cloud region two years ago, this collaboration has yielded tangible outcomes that directly support the objectives of Qatar National Vision 2030, particularly in enhancing digital infrastructure, delivering scalable and secure government services, and building a future-ready digital workforce." Mr. Sami added that "by providing access to cutting-edge cloud technologies, Google Cloud is empowering entities alike to innovate, improve service delivery, and accelerate progress across key sectors. Their contributions in areas such as artificial intelligence and data analytics are also playing a pivotal role in developing local digital talent and equipping our workforce with the skills needed for tomorrow's challenges. We are eager to continue this productive partnership, further solidifying Qatar's digital future and working in tandem to realize the ambitious goals of the Digital Agenda 2030 and Qatar National Vision 2030." Ghassan Kosta, Regional General Manager, Google Cloud Qatar, Oman, Bahrain and Iraq, said: "Today's Google Cloud Summit in Doha marks a truly pivotal moment in our Qatari journey, celebrating two years of our local cloud region and our strong partnerships. We are deeply honored by the continued collaboration with the Ministry of Communications and Information Technology and their trust in Google Cloud. This success is a shared achievement, magnified by the crucial contributions of all our partners and the inspiring innovation of our customers who join us in celebrating today. Together, by providing our advanced AI, data analytics, and secure cloud infrastructure through our local Doha region, we are committed to accelerating Qatar's digital transformation, empowering its public services, and energizing its dynamic digital economy." The Summit also highlighted how a diverse range of leading Qatari organizations are leveraging Google Cloud for their transformation journeys. These include Al Jazeera Media Network (AJMN), Aspire, beIN MEDIA GROUP, Media City Qatar, Ministry of Endowment & Islamic Affairs (Awqaf), Ministry of Labour, Ooredoo Group, Ooredoo Qatar, Qatar Airways, Qatar Foundation Pre-University Education, Qatar Free Zones Authority (QFZA), Qatar Insurance Company (QIC), Snoonu, University of Doha for Science and Technology (UDST) among many others who are driving innovation across various sectors.
Yahoo
a day ago
- Business
- Yahoo
Inaugural Global Business Summit in Jakarta convened to advance sustainable BRI Infrastructure Cooperation for SDGs
JAKARTA, Indonesia, May 31, 2025 /PRNewswire/ -- The "Inaugural Global Business Summit on Belt and Road Infrastructure Investment for Better Business Better World and Sustainable Development Goals" (the Summit) officially opened on May 25 in Jakarta. The Summit is co-hosted by the Government of Indonesia, the United Nations Global Compact "Sustainable Infrastructure for the Belt and Road Initiative to Accelerate the SDGs" Action Platform (UN Global Compact BRI for SDG Action Platform), THK Forum, United in Diversity Foundation (UID), the Indonesian Chamber of Commerce and Industry (KADIN), UN Global Compact Network Indonesia (IGCN), International Chamber of Commerce (ICC), and the Sustainable Development Solutions Network (SDSN). In keynote addresses, UN Under-Secretary-General Li Junhua emphasized the imperative for "low-carbon, resilient, and universally accessible infrastructure" while the UN Assistant Secretary General, and Executive Director of UN Global Compact Sanda Ojiambo outlined four strategic priorities for businesses: adopting science-based decarbonization targets, prioritizing circular economy principles, engaging local communities, and leveraging blended finance. Xiamen Airlines Chairman Zhao Dong highlighted the pivotal role of aviation connectivity in advancing the "Air Silk Road". The summit yielded substantive outcomes, including the launch of the report Transition Finance for Sustainable Development of Traditional Industries and nine cross-sector initiatives spanning green energy transition, SME empowerment, and global health cooperation. A landmark Joint Statement by the UNGC BRI for SDG Action Platform High-Level Steering Committee reaffirmed BRI's role as a global public good for infrastructure investments and business participation, committing to sustainable development through responsible business and multi-stakeholder partnerships across sectors including healthcare, energy, telecommunications, construction, manufacture, transportation, food, agriculture and digital infrastructure. Four expert roundtables addressed critical themes: sustainable supply chains in green minerals, healthcare innovation, ESG compliance, and green industrial park development. Marking the 75th anniversary of China-Indonesia diplomatic ties, UN resident coordinator's office in Indonesia and China joined hands with UN Global Compact company participants to co-launch Sino-Indonesia Corporate Communities Action Network for sustainable development to enhance sustainable communities and SDGs. Business leaders endorsed establishing an annual business summit mechanism to ensure BRI projects align with SDGs and promote international standard and private sector best practices. The summit concluded with a unified call to action, underscoring shared responsibility in building an inclusive, climate-resilient future through strengthened BRI collaboration. This inaugural event has established a new paradigm for public-private partnerships in sustainable infrastructure development, setting the stage for long-term, principled cooperation. View original content: SOURCE UN Global Compact
Yahoo
a day ago
- Business
- Yahoo
New Summit data could slow US approval plans for PD-1/VEGF drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A dual-acting drug developed by Summit Therapeutics and Akeso delayed tumor progression in a Phase 3 lung cancer trial but didn't extend survival, complicating its potential path to approval in the U.S. When administered alongside chemotherapy, the drug, known as ivonescimab, reduced the risk of death or disease progression by 48% compared to chemotherapy alone in patients whose non-small cell lung cancer has a mutation in a gene called EGFR. However, a 21% reduction in death risk, specifically, didn't meet the threshold for statistical significance, Summit said in a statement Friday. Summit intends to seek Food and Drug Administration approval based on the study results. Yet in its statement, the company indicated the timing of a filing is uncertain given the agency has made clear that a survival benefit is 'necessary' to support a submission. Summit shares fell by nearly 20% early Friday. Ivonescimab is the frontrunner among more than a dozen medicines that simultaneously block the proteins PD-1 and VEGF and are seen as a way to build upon widely used cancer immunotherapies like Keytruda. Its success or failure has broad implications for cancer research, making each study readout a closely scrutinized event among scientists and investors. So far, the results Summit and its China-based partner Akeso have accrued are painting a mixed and incomplete picture. A Phase 3 trial in China in non-small cell lung cancer found the drug cut the risk of disease progression or death in half compared to Keytruda, a striking, first-of-its-kind result that sparked interest and investment in PD-1/VEGF drugs. But ivonescimab hasn't yet clearly extended survival in that same study. Summit's drug also hasn't yet proven superior to the Keytruda-chemotherapy regimen that's standard therapy in many lung cancers. The results accrued so far were from trials in China, too, not the kind of multi-country test the FDA prefers. The data revealed Friday were meant to address one of those issues, proving that the benefits Summit and Akeso have observed in China would be replicated in a broader study population. Summit, for its part, said invonescimab's effects on tumor progression were 'clinically meaningful' in 'both Asia and ex-Asia sub-populations,' and demonstrated the 'consistency' of the drug's benefit in each group. The outcome also closely resembled what Akeso reported in a similar study of EGFR-mutated lung cancer in China. No new safety issues were observed either. The data 'demonstrates the potential benefit ivonescimab has to bring to patients around the world, including the United States,' said Summit chairman and co-CEO Robert Duggan, in a statement. Still, the lack of a clear impact on survival in the trial, at least so far, could slow ivonescimab's path to approval in the U.S. Summit implied its results could improve, as the follow-up time for 'western' patients in its trial was less than the median overall survival figure when data were analyzed. It also noted how no FDA-approved regimens in the setting in which ivonescimab was tested have demonstrated a statistically significant effect on survival. The FDA's insistence on such data, though, 'will weigh into Summit's considerations' as to when it might make a submission, the company said. The agency's 'high bar for demonstrated overall survival benefit make approval less likely,' wrote Leerink Partners analyst Daina Graybosch, in a Friday note to investors. Just this week, Merck and Daiichi Sankyo withdrew an approval application in EGFR lung cancer after a drug they've been developing failed to improve survival in a clinical trial. Summit will disclose specific findings at a future medical meeting. A study evaluating ivonescimab and chemotherapy against Keytruda and chemotherapy in non-small cell lung cancer is ongoing. A readout is expected in 2027, according to a federal database. Recommended Reading New Akeso, Summit data stir debate on PD-1/VEGF drugs
Associated Press
a day ago
- Business
- Associated Press
Real Mamas of Crypto Launches New Website and Announces June Summit
Expanding Digital Presence and In-Person Community for Mothers in Web3 NEW YORK - May 29, 2025 - Real Mamas of Crypto, a powerful network of 150+ accomplished mothers leading Web3 innovation, is proud to announce the launch of its newly redesigned website at . On the heels of this digital milestone, the organization will host its 'A Conversation with Crypto Moms' Summit on June 27th, 2025, bringing the industry together with mothers in the crypto community for conversation around the challenges and opportunities in the crypto space. The reimagined Real Mamas of Crypto website serves as a comprehensive hub featuring community highlights, upcoming events, and a way to join the community. By enhancing digital accessibility, Real Mamas aims to reach more senior-level mothers who seek authentic connection and practical guidance throughout their careers within web3. Motherhood has shown me the importance of prioritization and multigenerational thinking. This perspective is critical in an industry developing technology that will create significant cultural and societal shifts. The unique viewpoint that mothers bring is our greatest professional asset—one that society must recognize and value properly. - Joyce Lai, Esq. Founder of Real Mamas of Crypto. The June Summit represents RMC's commitment to fostering in-person connections within its growing community. This half-day event will welcome mothers, experts, and allies to engage in panel discussions, and networking opportunities focused on the challenges and opportunities in the crypto space. The program will include a virtual fireside chat with Securities and Exchange Commission Commissioner Hester Peirce, whom the crypto community colloquially refers to as the 'Crypto Mom.' She will be interviewed by Joyce Lai, Founder of New Territories LLC and Real Mamas of Crypto, and Thania Charmani, Partner at Winston & Strawn LLP. In addition, the program will include a featured panel titled 'What to Build? Hype vs. Signal for the Rest of 2025,' which will explore how founders and stakeholders can navigate market noise around tokenization and AI to focus on what truly matters. The panel will be moderated by Maria Adamjee, Director, Head of Institutional Affairs at Polygon. Speakers include Jay Biancamano, Strategic Advisor for Tokenization at Platonic, and Lei Lei, VP, Global Head of BD & Strategy at Kite AI. Registration for the June Summit is invite-only. For information on how to request an invitation, please visit . About Real Mamas of Crypto Founded in 2022, Real Mamas of Crypto is a growing group of 150+ senior-level mothers shaping web3's future. From grassroots beginnings, we've grown into a powerful network of executives, founders and partners across global tech hubs. Members represent leading protocols, VCs and financial institutions, sharing perspectives at the intersection of motherhood and digital innovation while supporting each other's professional and personal growth. For media inquiries, please contact [email protected].
Yahoo
a day ago
- Business
- Yahoo
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
Consistent Results Noted between Single Region HARMONi-A and Multiregional HARMONi Studies; Favorable Trends in Sub-Populations from North America and China for Both Primary Endpoints Were Observed Ivonescimab in Combination with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone; Positive Overall Survival Trend Observed with Hazard Ratio of 0.79 HARMONi Represents the First Phase III Trial to Evaluate Ivonescimab in a Multiregional Setting Summit to Determine Timing of US BLA Filing MIAMI, May 30, 2025--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab, successfully met the progression-free survival (PFS) primary endpoint and showed a positive trend in the other primary endpoint, overall survival (OS). HARMONi is a multiregional, double-blinded, placebo-controlled, Phase III study sponsored by Summit evaluating ivonescimab plus platinum-doublet chemotherapy compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with a 3rd generation EGFR tyrosine kinase inhibitor (TKI). This is a clinical setting with a patient population where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials in showing either a PFS or OS benefit. Approximately 38% of patients were randomized from western countries (ex-Asia), consistent with other recent multiregional Phase III studies in patients with EGFR-mutated NSCLC. At the prespecified primary data analysis, ivonescimab in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, with a hazard ratio of 0.52 (95% CI: 0.41 – 0.66; p<0.00001). PFS was measured by blinded independent central radiology review committee (BICR) compared to placebo in combination with chemotherapy. A clinically meaningful hazard ratio was observed in both Asia and ex-Asia sub-populations. The primary analysis demonstrated the consistency of the magnitude of the PFS benefit between patients randomized in Asia and ex-Asia, as well as the consistency in a single-region study (HARMONi-A) with this multiregional study. Ivonescimab in combination with chemotherapy showed a positive trend in OS in the primary analysis without achieving a statistically significant benefit with a hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057). This trend provides further support for its use in 2L+ EGFRm NSCLC, a setting where high unmet need continues to exist with limited approved options in the United States and other western territories. There are no current FDA-approved regimens that have demonstrated a statistically significant overall survival benefit in this patient setting. The median follow-up time for western patients was less than the median overall survival at the time of the analysis, and these patients may continue to be followed for long-term outcomes. Both Asian and North American patients demonstrated a positive trend in overall survival. The results of the primary analysis in this multiregional study were consistent with that of the single-region HARMONi-A study, which demonstrated an overall survival hazard ratio of 0.80 at 52% data maturity in a similar patient population. There were no new safety signals noted in this Phase III study. Grade 3 or higher treatment-emergent adverse events (TEAEs) were reported for 56.9% of patients in the ivonescimab + chemotherapy arm vs 50.0% with chemotherapy alone. Fatal TEAEs (excluding disease progression) were reported for 1.8% of patients in the ivonescimab + chemotherapy arm vs. 2.8% in those patients receiving chemotherapy alone. The safety profile of ivonescimab + chemotherapy was acceptable and manageable in the context of the observed clinical benefit. "The evidence of a consistent benefit in PFS for both Asian and western patients, as well as the consistent overall survival results between the single-region HARMONi-A study and our global HARMONi study demonstrates the potential benefit ivonescimab has to bring to patients around the world, including the United States," stated Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit Therapeutics. Based on the results of the HARMONi clinical trial, Summit, at present time, intends to file a Biologics License Application (BLA) in order to seek approval for ivonescimab plus chemotherapy in this setting. Based on discussions with the United States Food & Drug Administration (FDA), under our determination and subject to our review, Summit will consider the timing of the filing of this BLA. The FDA noted that a statistically significant overall survival benefit is necessary to support marketing authorization, which will weigh into Summit's considerations regarding the timing of a potential BLA filing. A more complete data presentation from the clinical study is intended to be shared at a future major medical conference. "Our conviction in the promise that this therapy holds for patients continues to be validated: we believe that ivonescimab has the potential to make a meaningful difference for the betterment of patients' lives," added Dr. Maky Zanganeh, President and Co-CEO of Summit. The positive Phase III HARMONi study results, along with the approval of ivonescimab in China in combination with chemotherapy based on the results of the HARMONi-A trial and the subsequent supplemental approval of ivonescimab monotherapy in China for first-line treatment of patients with advanced NSCLC whose tumors have positive PD-L1 expression based on the results of the HARMONi-2 trial, further substantiates the purposefully-engineered, differentiated mechanism of action of ivonescimab, a PD-1 / VEGF bispecific antibody evidencing cooperative binding characteristics, and its opportunity to improve upon the existing standards of care for solid tumors, including in settings where existing immune checkpoint inhibitors are indicated. We would like to offer our heartfelt gratitude to each of the patients, physicians, nurses, and caregivers who participated in and supported this clinical study. We are grateful to the dedication of our investigators and patients who are essential in advancing innovative therapies and bringing to patients the most advanced therapies for those facing unfortunate diagnoses. About Ivonescimab Ivonescimab, known as SMT112 in Summit's license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. Ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Ivonescimab's tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, SITC, 2023). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, SITC, 2023), is to improve upon previously established efficacy thresholds, in addition to side effects and safety profiles associated with these targets. Ivonescimab was engineered by Akeso Inc. (HKEX Code: and is currently engaged in multiple Phase III clinical trials. Over 2,300 patients have been treated with ivonescimab in clinical studies globally. Summit has begun its clinical development of ivonescimab in non-small cell lung cancer (NSCLC), commencing enrollment in 2023 in two multiregional Phase III clinical trials, HARMONi and HARMONi-3, and the Company has begun to enroll patients in the United States for HARMONi-7. HARMONi is a Phase III clinical trial which is evaluating ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a 3rd generation EGFR TKI (e.g., osimertinib). Top-line results were announced in May 2025, which included a statistically significant and clinically meaningful benefit in progression-free survival and a positive trend in overall survival, the trial's two primary endpoints. Consistent results were noted between the single region HARMONi-A study and the multiregional HARMONi study. HARMONi-3 is a Phase III clinical trial which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is a Phase III clinical trial which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression. In addition, Akeso has recently had positive read-outs in three single-region (China), randomized Phase III clinical trials for ivonescimab in NSCLC: HARMONi-A, HARMONi-2, and HARMONi-6. HARMONi-A was a Phase III clinical trial which evaluated ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with an EGFR TKI. Approximately 85% of patients received a 3rd generation EGFR-TKI prior to randomization in the study. HARMONi-2 is a Phase III clinical trial evaluating monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. HARMONi-6 is a Phase III clinical trial evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy in patients with locally advanced or metastatic squamous NSCLC, irrespective of PD-L1 expression. Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit's license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024, and its label was expanded in China in April 2025. Ivonescimab was granted Fast Track designation by the US Food & Drug Administration ("FDA") for the HARMONi clinical trial setting. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol "SMMT"). We are headquartered in Miami, Florida, and we have additional offices in Menlo Park, California, and Oxford, UK. For more information, please visit and follow us on X @SMMT_TX. Summit Forward-looking Statements Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the potential commercialization of the Company's product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program ("ATM Program"), the expected proceeds and uses thereof, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company's ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company's pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of filings that the Company makes with the Securities and Exchange Commission. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company's views only as of the date of this release and should not be relied upon as representing the Company's views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release. Summit Therapeutics and the Summit Therapeutics logo are trademarks of Summit Therapeutics 2025, Summit Therapeutics Inc. All Rights Reserved View source version on Contacts Contact Summit Investor Relations: Dave GancarzChief Business & Strategy OfficerNathan LiaBraatenSenior Director, Investor Relationsinvestors@ media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
